Kymera Therapeutics Inc
KYMR
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.85B
Close$
$-0.18
100.2% downside
Current Fair Value
100.2% downsideOvervalued by 100.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.85 Billion |
|---|---|
| Enterprise Value | $9.81 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.69 |
| Beta | 1.95 |
| Outstanding Shares | 98,177,158 |
Return
| Return on Equity | -19.85% |
|---|---|
| Return on Assets | -18.21% |
| Return on Invested Capital | -20.45% |
Valuation & Multiples
| P/E Ratio | -36.86 |
|---|---|
| PEG | 183.35 |
| Price to Sales | 121.38 |
| Price to Book Ratio | 8.09 |
| Enterprise Value to Revenue | 93.46 |
| Enterprise Value to EBIT | -30.55 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
$32.78 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.25
Average shareholder expectationRevenue Estimate
$3.82 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7552▼ 29.50% |
|---|---|
| Total Calls | 437,481▲ 285.45% |
| Total Puts | 330,400▲ 177.18% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.93%▼ 14.17% |
|---|---|
| Total Invested | $11.14B▲ 39.05% |
| Investors Holding | 286▲ 23.00% |
ESG Score
No data
About Kymera Therapeutics Inc
75 employeesKymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted...